Gasilin V S, Grigoriants R A, Lupanov V P, Lobova N M
Cor Vasa. 1983;25(1):10-6.
In a double blind trial the authors studied the effect of beta-adrenoblocking agent Trimepranol (Spofa, Czechoslovakia), in 35 patients with ischaemic heart disease (IHD) associated with angina pectoris, and in another 42 patients they compared the effect of Trimepranol and Obsidan (GDR). The daily doses of Trimepranol and Obsidan averaged 80-100 mg and 160-200 mg respectively. In two thirds of the patients the diagnosis of IHD was confirmed by coronary arteriography. In 46 patients the authors examined the tolerance of physical exercise before and after 3 to 4 weeks of Trimepranol and Obsidan therapy. Trimepranol was effective in 81% and Obsidan in 83% of patients with angina pectoris of effort. The two drugs were distinctly less effective in patients with both effort and resting angina pectoris (54 and 64% respectively). Trimepranol treatment was associated with a higher incidence of side-effects such as bradycardia, arterial pressure decrease and bronchial spasm than Obsidan treatment.
在一项双盲试验中，作者研究了β-肾上腺素能阻滞剂三甲丙醇（捷克斯洛伐克斯波法公司生产）对35例伴有心绞痛的缺血性心脏病（IHD）患者的疗效，并在另外42例患者中比较了三甲丙醇与奥西丹（德意志民主共和国生产）的疗效。三甲丙醇和奥西丹的日平均剂量分别为80 - 100毫克和160 - 200毫克。三分之二患者的IHD诊断经冠状动脉造影证实。作者对46例患者在接受三甲丙醇和奥西丹治疗3至4周前后的体育锻炼耐受性进行了检查。在劳力性心绞痛患者中，三甲丙醇的有效率为81%，奥西丹为83%。在劳力性和静息性心绞痛患者中，这两种药物的疗效明显较低（分别为54%和64%）。与奥西丹治疗相比，三甲丙醇治疗出现副作用（如心动过缓、动脉压下降和支气管痉挛）的发生率更高。
